Adjuvant immunotherapy after neoadjuvant immunochemotherapy and esophagectomy for esophageal squamous cell carcinoma: a real-world study

食管切除术 医学 佐剂 肿瘤科 免疫疗法 食管鳞状细胞癌 新辅助治疗 内科学 基底细胞 食管癌 普通外科 癌症 乳腺癌
作者
Jifeng Feng,Liang Wang,Xun Yang,Qixun Chen
出处
期刊:Frontiers in Immunology [Frontiers Media]
卷期号:15: 1456193-1456193 被引量:6
标识
DOI:10.3389/fimmu.2024.1456193
摘要

Background The role of immunotherapy in the adjuvant setting seems promising in recent years. As per the findings of the CheckMate 577 trial, patients with esophageal cancer (EC) who had neoadjuvant chemoradiation with residual pathologic disease should be considered adjuvant immunotherapy (AIT). However, it is unknown if individuals with esophageal squamous cell carcinoma (ESCC) who have received neoadjuvant immunochemotherapy (NICT) followed by radical surgery also require AIT. Methods A retrospective analysis was performed on the data from patients who underwent NICT and radical surgery for ESCC between 2019 and 2020. To compare disease-free survival (DFS) and overall survival (OS), Kaplan-Meier survival curves were produced. To determine the parameters linked to DFS and OS, a Cox model using hazard ratios (HRs) was completed. Results Among the 292 eligible patients, 215 cases with a mean age of 63.3 ± 6.8 years, including 190 (88.4%) men and 25 (11.6%) women, were finally recruited. The percentage of R0 resection was 98.3%. After NICT, 65 (30.2%) patients achieved pathological complete response. AIT was given to 78 (36.3%) patients following radical resection. For all patients, the 3-year DFS and OS were 62.3% and 74.0%, respectively. In terms of 3-year DFS (61.5% vs. 62.8%, P=0.984) or OS (76.9% vs. 72.3%, P=0.384), no statistically significant difference was found between patients with and without AIT. AIT significantly improved survival in patients with ypT+N+ (DFS: 23.9% vs. 38.5%, P=0.036; OS: 37.0% vs. 61.5%, P=0.010), but not in those with ypT0N0 or ypT+N0. It was found that AIT was related to both DFS (HR: 0.297; P<0.001) and OS (HR: 0.321; P=0.001) in patients with ypT+N+. Conclusion In ypT+N+ ESCC patients, AIT after NICT followed by radical surgery reduces the recurrence and death, thereby improving the DFS and OS. Randomized controlled trials ought to be conducted to further assess the results of this retrospective investigation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
科目三应助陈小露采纳,获得10
2秒前
2秒前
hh完成签到,获得积分10
5秒前
DKJ应助常泽洋122采纳,获得10
7秒前
胡图图发布了新的文献求助10
8秒前
仲半邪完成签到,获得积分10
8秒前
gjy发布了新的文献求助10
8秒前
DAY完成签到 ,获得积分10
10秒前
13秒前
herrmayor完成签到,获得积分10
13秒前
13秒前
Hase完成签到 ,获得积分10
13秒前
Jasper应助gjy采纳,获得10
14秒前
文文武完成签到 ,获得积分10
15秒前
16秒前
16秒前
彩色夜阑完成签到,获得积分10
18秒前
20秒前
123完成签到,获得积分10
20秒前
21秒前
明亮的嚣发布了新的文献求助10
21秒前
花痴的手套完成签到 ,获得积分10
21秒前
23秒前
科研通AI6.4应助ky一下采纳,获得10
23秒前
23秒前
ding完成签到 ,获得积分10
24秒前
fighter完成签到,获得积分10
25秒前
机灵凝蕊完成签到,获得积分10
26秒前
27秒前
28秒前
陈小露发布了新的文献求助10
28秒前
蓝星花完成签到 ,获得积分10
29秒前
无限乘云发布了新的文献求助30
30秒前
31秒前
慕青应助胖头鱼采纳,获得50
32秒前
32秒前
molihuakai应助baobaoxiong采纳,获得10
33秒前
Kuku完成签到,获得积分10
33秒前
33秒前
高分求助中
Principles of Economics, 11th Edition 10000
Prescott's Microbiology: 2026 Release ISE 10000
University Physics with Modern Physics, 16th edition 10000
Cronologia da história de Macau 5000
Environmental Leverage in Times of Climate Crisis: Product Standards, Carbon Border Measures and Preferential Trade Agreements 1000
Interactions of Vowel Quality and Prosody in East Slavic 1000
Erwählung und Berufung bei Paulus: Bedeutung, Entwicklung und Funktion einer Vorstellung in ihrem frühjüdischen und griechisch-römischen Kontext 850
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7151232
求助须知:如何正确求助?哪些是违规求助? 8796902
关于积分的说明 18590911
捐赠科研通 6748730
什么是DOI,文献DOI怎么找? 3159711
关于科研通互助平台的介绍 2292425
邀请新用户注册赠送积分活动 2134314